APA

Eigentler T. K., Kamin A., Weide B. M., Breuninger H., Caroli U. M., Möhrle M., Radny P. & Garbe C. (20071009). A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. : Journal of the American Academy of Dermatology.

Chicago

Eigentler Thomas K, Kamin Anne, Weide Benjamin M, Breuninger Helmut, Caroli Ulrich M, Möhrle Matthias, Radny Peter and Garbe Claus. 20071009. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. : Journal of the American Academy of Dermatology.

Harvard

Eigentler T. K., Kamin A., Weide B. M., Breuninger H., Caroli U. M., Möhrle M., Radny P. and Garbe C. (20071009). A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. : Journal of the American Academy of Dermatology.

MLA

Eigentler Thomas K, Kamin Anne, Weide Benjamin M, Breuninger Helmut, Caroli Ulrich M, Möhrle Matthias, Radny Peter and Garbe Claus. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. : Journal of the American Academy of Dermatology. 20071009.